This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.
The epidemic of the COVID-19 has expanded from Wuhan through out China, and is being exported
to a growing number of countries. Recently, investigators have revealed that acute myocardial
injury is existed in 7.2% patients with COVID-19, and this proportion in patients admitted to
the ICU (22.2%) is higher than patients not treated in the ICU (2.0%). Thus, cardiac troponin
I (cTNI), the biomarker of cardiac injury, might be a clinical predictor of COVID-19 patient
outcomes. This study aims to investigate the clinical characteristics, the incidence of
myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19
patients.
Other: non
no intervention
Inclusion Criteria:
- (1) Age ≥18 years. (2) Laboratory (RT-PCR) confirmed infection with SARS-CoV-2. (3)
Lung involvement confirmed with chest imaging.
Exclusion Criteria:
- No cTnI test on admission
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China